High expression of PARP1 in AML patients correlates with a poor prognosis, and with the frequency of mutations in FTL3-ITD and DNA (cytosine-5)-methyltransferase 3A (DNMT3a) [142]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.